A team of researchers from Toulouse recently identified new bacteria present in the livers of people affected by Nash’s disease, more commonly known as “fatty liver disease”, which could affect 400,000 people in France by 2030.
A scientific breakthrough. Toulouse researchers recently discovered the presence of new bacteria in the livers of people affected by Nash’s disease (non-alcoholic steatohepatitis), from the moment it was triggered, revealed our colleagues from La Dépêche.
Commonly known as “fatty liver disease”, this pathology now affects more than 200,000 people in France, and should affect more than 400,000 cases in 2030, according to projections by the French National Society of Gastro-Enterology (SNFGE) .
“Our results suggest that specific bacteria could be responsible for the deposit of fibrosis in the liver, at the first stage of the disease”, explained to the regional daily Professor Rémy Burcelin, director of research at Inserm and leader of the team. of Toulouse research. Hepatic fibrosis corresponds to an acceleration of the healing of the tissues present in the liver, and leads to the most serious form from which many patients with Nash’s disease suffer, namely cirrhosis.
No processing allowed on the market
As the SNFGE recalls, no treatment against fatty liver disease “currently has marketing authorization (AMM)”. This absence of a drug solution does not however sound like an acknowledgment of failure for people suffering from this pathology since weight loss makes it possible, in the majority of cases, to cure.
Still according to this same source, “weight loss allows reversibility of inflammation or even hepatic fibrosis”, and, if the loss corresponds to 10% of body mass, we observe a “disappearance of steatohepatitis in 90% cases”, can we read on the organization’s website.
The French National Society of Gastro-Enterology also specifies that 25% of liver cancers affect people suffering from Nash’s disease.